Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.2052W HIGH $17.15
Volume
181.97 K
Value Traded
2.03 M
Short % Float
9.37%
-0.79%Week
-3.55%1 Month
-8.36%3 Month
-12.4%6 Month
-71.6%5 Year
-3.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
364.07 M
EPS (TTM)
-2.17
P/E Ratio
-
Ent. Value
152.57 M
Total Shares
29.13 M
Float Shares
27.75 M
Insiders
4.74%
Institutions
94.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ENTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Enanta Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enanta Pharmaceuticals, Inc.
343Total events
8Upcoming
88Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
●IND SubmissionEPS-3903IND
IND filing for EPS-3903 (oral STAT6 inhibitor)
type 2 inflammatory diseasessource ↗
▲First Patient DosedzelicapavirTrial
Dosing began in LOTUS Phase 2b pediatric trial of zelicapavir
RSV infection in pediatric patientssource ↗
●IP Litigation RulingIP / Competition
Combined petition for panel or en banc rehearing filed with Federal Circuit
▲EU ApprovalMAVIRETApprovedEx-US Regulatory
European Commission approval of MAVIRET for acute hepatitis C
acute hepatitis C virussource ↗
▲Trial InitiationzelicapavirTrial
Advancement of zelicapavir clinical development program
Respiratory Syncytial Virus (RSV)source ↗
●End Of Phase 2 MeetingzelicapavirFDA Meeting
End-of-Phase 2 meeting with FDA for zelicapavir
RSV infectionsource ↗
▲EU ApprovalMAVIRETApprovedEx-US Regulatory
European Commission approval of MAVIRET for acute HCV infection
acute hepatitis C virus (HCV) infection in adults and children aged three years and oldersource ↗
▼IP Litigation RulingIP / Competition
Federal Circuit affirmed summary judgment invalidating U.S. Patent No. 11,358,953 claims
◆Oral PresentationPresentation
Presentation of RSV program data at ATS 2026
Respiratory Syncytial Virussource ↗
●Poster PresentationzelicapavirPresentation
Zelicapavir data presented at ATS International Conference 2026
RSV infectionsource ↗
●Poster PresentationEPS-3903Presentation
EPS-3903 data presented at ATS International Conference 2026
atopic dermatitissource ↗
▲First Patient DosedEDP-978Trial
First participant dosed in Phase 1 clinical trial of EDP-978
Urticariasource ↗
●Timing GuidancezelicapavirPresentation
Update on development path for zelicapavir pivotal study
RSV infection in adults at high risksource ↗
▲First Patient DosedEDP-978Trial
First participant dosed in Phase 1 trial of EDP-978
chronic urticariasource ↗
●Poster PresentationzelicapavirPresentation
Zelicapavir data presented at ESCMID Global Conference 2026
RSV infectionsource ↗
●Poster PresentationEPS-3903Presentation
EPS-3903 data presented at American Association of Immunology Conference
atopic dermatitissource ↗
◆Oral PresentationPresentation
Management participation in fireside chat at The Citizens Life Sciences Conference
◆Poster PresentationEDP-978Presentation
EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans
mast cell-mediated, Type 2 immune diseasessource ↗
▲First Patient DosedEDP-978Trial
Dosing initiation in Phase 1 trial of EDP-978
chronic urticariasource ↗
▲Development Candidate NominationEPS-3903Preclinical
EPS-3903 nominated as lead development candidate for STAT6 inhibitor program
type 2 immune-driven diseasessource ↗
▲Development Candidate NominationEDP-978Preclinical
EDP-978 nominated as clinical candidate for KIT inhibitor program
mast-cell driven diseasessource ↗
●Oral PresentationEDP-323Presentation
Oral presentation of EDP-323 challenge study at IDWeek 2025
RSV infectionsource ↗
●Poster PresentationzelicapavirPresentation
Poster presentation of zelicapavir pediatric data at IDWeek 2025
RSV infection in pediatric patientssource ↗
●Poster PresentationEDP-323Presentation
Poster presentation of EDP-323 PEP analysis at IDWeek 2025
RSV infectionsource ↗
▲Topline ReadoutzelicapavirClinical Data
Positive topline results from Phase 2b study of zelicapavir in high-risk adults with RSV
Respiratory Syncytial Virus (RSV)source ↗
◆Topline ReadoutzelicapavirClinical Data
Topline data for RSVHR trial expected in September
Respiratory Syncytial Virus (RSV)source ↗
◆IP Litigation RulingIP / Competition
Enanta files patent infringement suit against Pfizer in UPC over Paxlovid
COVID-19source ↗
▲FDA ApprovalMAVYRETApprovedFDA Decision
FDA approval of expanded indication for MAVYRET in acute HCV
Acute hepatitis C virus (HCV)source ↗
●Quarterly UpdateCorporate
Fiscal Q3 2025 financial results press release planned for August 11, 2025
◆Topline ReadoutzelicapavirClinical Data
Topline data for RSVHR Phase 2 study of zelicapavir in high-risk adults
RSV in high-risk adultssource ↗
◆Development Candidate NominationPreclinical
STAT6 development candidate selection expected in 2H 2025
Inflammatory diseasessource ↗
▲Enrollment CompletezelicapavirTrial
Enrollment completed in RSVHR trial with 186 patients
Respiratory Syncytial Virus (RSV) infection in high-risk adultssource ↗
▲Enrollment CompletezelicapavirTrial
Met target enrollment of 180 patients in RSVHR Phase 2 study of zelicapavir
RSV infection in high-risk adultssource ↗
▲Oral PresentationzelicapavirPresentation
Data presented at ESPID 2025 Conference
RSV infection in pediatric patientssource ↗
◆Enrollment CompletezelicapavirTrial
Enrollment to complete in late May 2025
RSV infection in high-risk adultssource ↗
◆Development Candidate NominationPreclinical
STAT6 inhibitor development candidate selection expected in 2H 2025
Inflammatory diseases (STAT6-mediated)source ↗
◆IP Litigation RulingIP / Competition
Opening brief filed with Federal Circuit in patent infringement case against Pfizer regarding Paxlovid
●Oral PresentationEDP-323Presentation
Oral presentation of EDP-323 Phase 2 human challenge study at RSV2025
RSV infectionsource ↗
Past FDA Catalysts and PDUFA Decisions
How ENTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | zelicapavir | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$212M
Pipeline Value
Overvalued
Valuation Signal
8
Drugs Scored
0.6x
rNPV / MCap
Top 33%
Micro Cap(rank 218 of 658)
Percentile Rank
Enanta Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $530M risk-adjusted pipeline value, led by EDP-235 in COVID-19 (Phase 2), across $101B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EDP-235 Small moleculeCompletedNCT05594615 | COVID-19 | Phase 2 | COMPLETED | 291 | Nov 18, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ENTA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zelicapavir | Respiratory Syncytial Virus (RSV) | Phase 2b | 2025-11-17 | In the Phase 2b RSVHR study, zelicapavir demonstrated a clinically meaningful reduction in time to complete resolution of RSV symptoms by 2.2 days for the overall efficacy population and 6.7 days for high-risk patients (p<0.001).Read More | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -EndedRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vance TerryDirector | Grant/Award | 20,000 20,000 held | $0.00 | 03/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ENTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 15.9 % (12 %) | 41.79 M | 2.87 M |
ENTA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENTA ranks across every disease it competes in
Competitive Position is a premium feature
See how ENTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENTA News
ENTAEnanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals, a clinical-stage biotech firm, will participate in two investor conferences in September 2026. The events include a fireside chat at the Baird 2026 Global Healthcare Conference and another at the H.C. Wainwright 28th Annual Global Investment Conference. This engagement highlights the company's commitment to investor relations.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals reported its financial results for the fiscal third quarter ending June 30, 2026. The company highlighted progress in its respiratory syncytial virus (RSV) and immunology programs, including the initiation of dosing in the Phase 2 LOTUS trial. CEO Jay R. Luly emphasized the momentum in their ongoing projects.
Read more →ENTA▲ +5.2%on this news
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Enanta Pharmaceuticals' partner, AbbVie, has received approval from the European Commission for MAVIRET® (glecaprevir/pibrentasvir) to treat individuals with acute Hepatitis C virus. This approval is significant as it expands the treatment options available for patients suffering from this condition. The approval highlights the ongoing efforts to combat Hepatitis C effectively.
Read more →ENTAEnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals has announced progress in its clinical development program for Zelicapavir, aimed at treating Respiratory Syncytial Virus (RSV). The announcement highlights the company's ongoing efforts in addressing this viral infection. Further details on the program's advancements were not provided in the article.
Read more →ENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2026
Enanta Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Jay R. Luly and Chief Product Strategy Officer Tara L. Kieffer will participate in a fireside chat. The event will be accessible via a live webcast, with a replay available for 30 days. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases.
Read more →ENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals is scheduled to present at the Jefferies Global Healthcare Conference. The event will provide an opportunity for the company to discuss its latest developments and strategies with investors and industry peers. Further details regarding the presentation have not been disclosed.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals has reported its financial results for the fiscal second quarter ending March 31, 2026. The report includes key financial metrics and insights into the company's performance during this period. Details regarding revenue, expenses, and future outlook are highlighted, reflecting the company's current standing in the biopharma sector.
Read more →ENTAEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals is set to present data regarding its Respiratory Syncytial Virus and STAT6 inhibitor programs at the upcoming American Thoracic Society International Conference in 2026. The presentation aims to highlight the company's advancements in these therapeutic areas. Further details on the data to be presented have not been disclosed.
Read more →ENTAEnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-978, an oral KIT inhibitor aimed at treating chronic urticaria. The trial will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults. With chronic urticaria affecting patients' quality of life, EDP-978 may provide a new treatment option for those resistant to existing therapies. Topline results are expected in Q4 2023.
Read more →ENTAEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals is set to present data on Zelicapavir, an oral, once-daily N-Protein inhibitor aimed at treating Respiratory Syncytial Virus (RSV). This presentation will take place at the ESCMID Global 2026 event. The focus on RSV treatment highlights the ongoing research in antiviral therapies.
Read more →ENTAEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals is set to present data regarding its STAT6 inhibitor program at the upcoming IMMUNOLOGY2026TM conference. This annual meeting is organized by the American Association of Immunologists (AAI). The presentation is expected to highlight advancements in the company's research efforts.
Read more →ENTAEnanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026. The event will take place in Miami Beach, FL, and will be accessible via a live webcast. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases, with current programs targeting respiratory syncytial virus and inflammatory diseases.
Read more →ENTAEnanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals announced that it will present preclinical data for EDP-978, a KIT inhibitor aimed at treating mast cell-mediated Type 2 immune diseases, at the 2026 AAAAI Annual Meeting. The presentations will take place on February 27, 2026, in Philadelphia, PA. Two posters will detail the drug's potency and pharmacokinetic profile.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals reported its financial results for the fiscal first quarter ending December 31, 2025, highlighting advancements in its RSV treatment portfolio and immunology pipeline. The company recorded total revenue of $18.6 million, primarily from royalties on AbbVie's MAVYRET. Despite a net loss of $11.9 million, Enanta maintains a strong cash position to support its development programs into fiscal 2029.
Read more →ENTAEnanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Jay R. Luly will discuss the company's innovative approaches to drug development, particularly in virology and immunology. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →ENTA▲ +6.3%on this news
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025
Enanta Pharmaceuticals announced its financial results for the fiscal fourth quarter and year ending September 30, 2025. The company achieved significant progress in its virology and immunology programs, notably with positive data from its Phase 2b RSVHR study. Enanta plans to file an IND for its oral STAT6 inhibitor EPS-3903 in 2026, while maintaining a healthy cash position to fund future operations. Despite a decrease in overall revenue due to declining royalties from AbbVie, the company remains focused on developing treatments for viral and immunological diseases.
Read more →ENTA▲ +91.9%on this newsshared move
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Enanta Pharmaceuticals has reported positive topline results from its Phase 2b study of Zelicapavir for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution time in patients with conditions like congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Additionally, Zelicapavir showed a significantly lower hospitalization rate compared to placebo and met several secondary endpoints for virology and safety. These findings support the potential of Zelicapavir as a new treatment for RSV in vulnerable adult populations.
Read more →ENTA▲ +91.9%on this newsshared move
This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development progra
Enanta Pharmaceuticals has presented forward-looking statements about its business and the development of Zelicapavir for treating Respiratory Syncytial Virus (RSV) in high-risk adults. Initial results suggest a favorable safety profile and a clinically meaningful reduction in symptom duration. However, the future success of Zelicapavir will depend on the outcomes of further studies, emphasizing uncertainty in predictions. The company urges caution regarding reliance on forward-looking statements and acknowledges the existing risks and uncertainties.
Read more →About Enanta Pharmaceuticals, Inc.
Headquarters4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next ENTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime